AOD-9604

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, specifically amino acids 176–191. It was originally developed as a potential anti-obesity fragment because it may promote fat metabolism while avoiding many of the effects associated with full-length growth hormone. It is of interest for body composition and metabolic research.

• Fat loss and body composition
• Enhanced lipolysis, the breakdown of stored fat
• Support for healthy metabolic function
• Potential applications in obesity research
• Cartilage and joint health research
• General metabolic health research

• May promote lipolysis, the breakdown of stored fat
• May inhibit lipogenesis, the formation of new fat
• Targets fat tissue directly, without a significant impact on glucose regulation, IGF-1, or insulin
• May support improvements in body composition and metabolic health

Reconstitution

1 mL acetic acid or bacteriostatic water

Final concentration

5 mg/mL

Starting dose

0.5 mg (10 units)

Frequency

Daily

Cycle duration

90–120 days

Administration

Subcutaneous injection in the morning

Storage

Refrigerate after reconstitution

Notes

The sheet notes morning subcutaneous injection, and that it is best studied if paired with another metabolic peptide.

Research duration on the sheet: 90–120 days on the source sheet.

• 5 mg + 1 mL acetic acid or bacteriostatic water = 5 mg/mL.
• 10 units = 0.5 mg.

• The sheet lists 0.5 mg (10 units) once daily.
• Dose and duration may be adjusted based on the specific research objective.

• For research and educational purposes only.
• Not for human consumption.
• Conduct research in accordance with applicable laws and regulations.

Research status on the sheet

Investigational peptide, research use only

Completed published studies are listed below and labeled as in vitro, animal, or human research. Favorable and unfavorable results are both included, including cancer studies. This is not every paper on the compound, and it is not a recommendation or a dose.

The weight-loss signal is from mice. A later, larger human obesity program did not confirm a clear weight-loss benefit, and that larger trial was not published as a primary paper. The breast-cancer experiment used growth-hormone fragment 176–191, the sequence AOD-9604 is modified from, not AOD-9604 itself.

• AOD9604 increased fat oxidation and weight loss in obese miceAnimal

  Obese mice. Chronic treatment with this growth-hormone fragment increased fat oxidation and reduced weight.

• AOD9604 and lipid metabolism in obese mice and beta-3 receptor knockout miceAnimal

  Obese mice lost weight and body fat over 14 days. The same weight change did not occur in mice lacking the beta-3 adrenergic receptor.

• Growth-hormone fragment 176–191 with doxorubicin in breast cancer cellsIn vitro

  MCF-7 breast cancer cells. The unmodified fragment, loaded with doxorubicin into nanoparticles, made the drug slightly more toxic to the cells. The peptide by itself did not kill them.

5 mg vial. Format: Lyophilized powder.